iifl-logo

Kilitch Drugs (India) Ltd Board Meeting

445
(0.91%)
Aug 1, 2025|12:00:00 AM

Kilitch Drugs CORPORATE ACTIONS

02/08/2024calendar-icon
02/08/2025calendar-icon
PurposeBoard Meetings DateAnnouncement Date
Board Meeting12 Jul 202512 Jul 2025
Board meeting to approve issue period and letter of offer Submission of Corrigendum of Outcome of Board meeting held on July 12, 2025
Board Meeting9 Jul 20259 Jul 2025
Issue of equity shares of company on right issue basis Board of Directors meeting held today, i.e., July 9, 2025, has, inter alia, considered and approved the following terms of the Rights Issue: Total number of securities proposed to be 13,98,463 fully paid-up Equity Shares of issued 2 (Two) Rights Equity Shares of 210/ - each for every 23 (Twenty-Three) Equity Shares of %10/ - each held by the Eligible Equity Shareholders in the Company as on the record date, with the right to renounce. Issue Price Rs. 357/- per Rights Equity Share (including premium of 347/- per Rights Equity Share and Face Value of 10/ - each). Outstanding Equity Shares prior to the 1,60,82,319 Equity Shares of 10/- each Rights Issue Outstanding Equity Shares post Rights 1,74,80,782 Equity Shares of %10/- each Issue (assuming full subscription) (assuming full subscription).
Board Meeting2 Jul 202529 Jun 2025
Kilitch Drugs India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/07/2025 inter alia to consider and approve for fund raising by way of issue of equity shares through right issue through right issue Raising of Fund by way of issue of equity shares of the company on right issue basis (As Per BSE Announcement Dated on :02.07.2025)
Board Meeting19 May 202513 May 2025
Kilitch Drugs India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/05/2025 inter alia to consider and approve Audited Standalone and Consolidated Financial Results for the quarter ended 31st March 2025 Outcome of Board Meeting (As Per BSE Announcement Dated on: 19/05/2025)
Board Meeting11 Feb 20253 Feb 2025
KILITCH DRUGS (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/02/2025 inter alia to consider and approve unaudited standalone and consolidated financial results for the quarter ended 31st December 2024 Considered and Approved unaudited financial results for quarter ending 31st December, 2024 (As per BSE Announcement Dated on 11/02/2025)
Board Meeting12 Nov 20244 Nov 2024
KILITCH DRUGS (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2024 inter alia to consider and approve unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended 30th September 2024. We are submitting herewith the financial results for the quarter ended 30th September, 2024 (As Per BSE Announcement Dated on: 12/11/2024)
Board Meeting30 Aug 202430 Aug 2024
Pursuant to Regulation 30 of SEBI LODR Regulations, this is to inform you that the Board of Directors approved the appointment of M/s C Sharat & Company, Chartered Accountants as a Statutory Auditors of the Company
Board Meeting26 Aug 202426 Aug 2024
Appointment of M/s. AVHP & Company LLP, Chartered Accountant (FRN:W100671) as Statutory Auditors of the Company
Board Meeting8 Aug 20241 Aug 2024
KILITCH DRUGS (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2024 inter alia to consider and approve unaudited financial results for the period ended 30th June 2024 Submission of Quarterly Standalone and Financial Results for the quarter ended 30th June 2024 (As Per BSE Announcement Dated on: 08/08/2024)

Kilitch Drugs: Related News

No Record Found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.